Martinsried, Germany

Mark Rutz

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 12.4

ph-index = 4

Forward Citations = 49(Granted Patents)


Location History:

  • Lena-Christ-Strasse, DE (2013)
  • Martinsfried, DE (2016)
  • Martinsried, DE (2013 - 2018)

Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Mind of Mark Rutz: A Pioneer in Viral Infection Treatment

Introduction: Mark Rutz is an accomplished inventor based in Martinsried, Germany, with a significant portfolio of 9 patents. His work focuses on advancing medical treatments through innovative approaches, especially in the realm of viral infections and inflammatory conditions.

Latest Patents: Among Mark Rutz's most notable contributions are his latest patents that detail methods of reducing clinical symptoms of viral infections. These patents include techniques for administering toll-like receptor 3 (TLR3) antibody antagonists and polynucleotides encoding these antagonists or their fragments. Furthermore, he has developed methods for treating inflammatory conditions using these TLR3 receptor antagonists, showcasing his commitment to leveraging scientific research for groundbreaking medical solutions.

Career Highlights: Mark Rutz contributes his expertise to Janssen Biotech, Inc., a well-respected company known for its focus on innovative pharmaceuticals. His dedication to developing new treatment methods has marked him as a significant figure in the field of biotechnology and medicine.

Collaborations: Throughout his career, Mark has worked alongside esteemed colleagues such as Jinquan Luo and Robert Rauchenberger. Their collaboration has helped drive forward the research and development vital for the innovation of therapies targeting viral infections and inflammation.

Conclusion: Mark Rutz’s contributions to medical innovation through his patents and collaborative efforts have positioned him as an influential inventor in the biotechnology sector. His work at Janssen Biotech, Inc. continues to pave the way for new therapeutic options, addressing critical health challenges related to viral infections and inflammation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…